Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Warns Lupin Again About Poor Batch Failure Investigations

Oct 03 2019

• By Joanne S. Eglovitch

WarningSign_1200x675 — FDA Wants Lupin To Up Its OOS Game • Source: Shutterstock

Related Content

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Jan 07 2019

FDA Warning Letter Hits Akorn’s Subpar Root Cause Investigations

Jul 10 2019

Aurobindo Faulted In US FDA Warning Letter For Poor Root Cause Investigations

Jul 03 2019

FDA: Key FY 2019 Warning Letter Trend Is Inadequate Testing For API Impurities

Sep 20 2019

The Quality Lowdown: Quality Vision Falls Short At Various US and Indian Facilities

Jun 10 2019

FDA Warning Letter To Teva Highlights Need For Accurate Root Cause Investigations

Mar 11 2019

FDA Warns Lupin To Stop Blaming Lab And Fix Manufacturing Processes

Nov 16 2017

Related Companies

Lupin Limited

Additional Topics

United States India Asia Pacific Manufacturing Quality Enforcement BioPharmaceutical

More from Manufacturing

More from Compliance

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window